Pierre P. Massion, MD, Richard M. Caprioli, PhD 

Slides:



Advertisements
Similar presentations
Genomes and Proteomes genome: complete set of genetic information in organism gene sequence contains recipe for making proteins (genotype) proteome: complete.
Advertisements

Cathy Eng M.D., Salil Sethi M.D., George J.Chang, M.D., Miguel A. Rodriguez-Bigas, M.D., John M. Skibber, M.D., Jianjun Shen Ph.D., Jijiang Zhu Ph.D.,
Lecture 9. Functional Genomics at the Protein Level: Proteomics.
Matrix-Assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF) Mass spectrometry for protein identification 2-Dimensional Gel Electrophoresis MALDI-TOF.
Proteomics Informatics – Overview of Mass spectrometry (Week 2)
Prognostic Stratification of Stage IIIA pN2 Non-small Cell Lung Cancer by Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data: An.
Naomi Fujioka, MD, Christopher A. French, MD, Michael J
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Genomic analysis: Toward a new approach in breast cancer management
S. Emonet, H.N. Shah, A. Cherkaoui, J. Schrenzel 
Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.
Using Laser Raman Spectroscopy to Reduce False Positives of Autofluorescence Bronchoscopies: A Pilot Study  Michael A. Short, PhD, Stephen Lam, MD, Annette.
2D-Gel Analysis Jennifer Wagner
Proteomic Serum Profile of Fatigued Men Receiving Localized External Beam Radiation Therapy for Non-Metastatic Prostate Cancer  Nada Lukkahatai, PhD,
Pinar B. Yildiz, MD, Yu Shyr, PhD, Jamshedur S. M. Rahman, PhD, Noel R
Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization.
Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, a revolution in clinical microbial identification  A. Bizzini, G. Greub 
AZGP1 Autoantibody Predicts Survival and Histone Deacetylase Inhibitors Increase Expression in Lung Adenocarcinoma  Daniel L. Albertus, BS, Christopher.
Proteomics, oxidative stress and male infertility
Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non–Small Cell Lung Cancer  Chao Li, MD, PhD,
Kenneth Song, Samir Hanash  Gastroenterology 
Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Identification and Validation of Long Noncoding RNA Biomarkers in Human Non–Small- Cell Lung Carcinomas  Hui Yu, MD, Qinghua Xu, PhD, Fang Liu, PhD, Xun.
Figure 1 Schematic representation of a typical MALDI-MSI workflow
Detection of microorganisms in blood specimens using matrix-assisted laser desorption ionization time-of-flight mass spectrometry: a review  M. Drancourt 
A perspective on proteomics in cell biology
Proteomics in cardiovascular surgery
Thyroid Transcription Factor-1 Amplification and Expressions in Lung Adenocarcinoma Tissues and Pleural Effusions Predict Patient Survival and Prognosis 
S. Emonet, H.N. Shah, A. Cherkaoui, J. Schrenzel 
Prognostic Stratification of Stage IIIA pN2 Non-small Cell Lung Cancer by Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data: An.
Co-Overexpression of Cyclooxygenase-2 and Microsomal Prostaglandin E Synthase-1 Adversely Affects the Postoperative Survival in Non-small Cell Lung Cancer 
The potential for proteomic definition of stem cell populations
Interpretation of Anti-ALK Immunohistochemistry Results
The potential for proteomic definition of stem cell populations
Volume 2, Issue 4, Pages (April 2016)
Proteomic analysis of filaggrin deficiency identifies molecular signatures characteristic of atopic eczema  Martina S. Elias, BSc, Heather A. Long, PhD,
Lung Cancer Serum Biomarker Discovery Using Label-Free Liquid Chromatography- Tandem Mass Spectrometry  Xuemei Zeng, PhD, Brian L. Hood, PhD, Ting Zhao,
Volume 143, Issue 3, Pages e2 (September 2012)
Comprehensive Computational Pathological Image Analysis Predicts Lung Cancer Prognosis  Xin Luo, MD, Xiao Zang, BS, Lin Yang, MD, Junzhou Huang, PhD,
Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with.
Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors  Benny Weksler, MD, Anthony Holden, MD, Jennifer.
Characterization of Lymphomas Developing in Immunodeficient Mice Implanted With Primary Human Non–Small Cell Lung Cancer  Thomas John, MBBS, PhD, Naoki.
Christina I. Selinger, PhD, Wendy A
Role of Chromosome 3q Amplification in Lung Cancer
Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.
Expression profiling Journal of Allergy and Clinical Immunology
Mass Spectrometry THE MAIN USE OF MS IN ORG CHEM IS:
Is Proteomics the New Genomics?
High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer  Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.
Clinical Significance of Epidermal Growth Factor Receptors in Non-small Cell Lung Cancer and a Prognostic Role for HER2 Gene Copy Number in Female Patients 
The Prognostic Significance of Focal Adhesion Kinase Expression in Stage I Non– Small-Cell Lung Cancer  Grace K. Dy, MD, Lourdes Ylagan, MD, Saraswati.
A Comprehensive Analysis of p16 Expression, Gene Status, and Promoter Hypermethylation In Surgically Resected Non-small Cell Lung Carcinomas  William.
Erratum Journal of Thoracic Oncology
Loss of p16INK4A Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas  Scott W. Aesif, MD,
ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers  Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.
Mitotic Inhibitors Journal of Thoracic Oncology
Impact of a Multidisciplinary Thoracic Oncology Clinic on the Timeliness of Care  Richard F. Riedel, MD, Xiaofei Wang, PhD, Meg McCormack, PA-C, Eric Toloza,
Use of MicroRNA Expression Levels to Predict Outcomes in Resected Stage I Non- small Cell Lung Cancer  Eric Duncavage, MD, Boone Goodgame, MD, Ananth Sezhiyan,
CXCR4 Overexpression Is Associated with Poor Outcome in Females Diagnosed with Stage IV Non-small Cell Lung Cancer  Shannon Otsuka, MSc, Alexander C.
It’s All in the “Swerve of the Curve”
Serum Proteomic Profiling of Lung Cancer in High-Risk Groups and Determination of Clinical Outcomes  William Jacot, MD, PhD, Ludovic Lhermitte, MD, Nadège.
EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers
Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non–Small Cell Lung Cancer  Murry.
Non-invasive Breath Analysis of Pulmonary Nodules
Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern.
FGFR1 Amplification in Squamous Cell Carcinoma of The Lung
General schematic for MS analysis of ionized microbiological isolates and clinical material. General schematic for MS analysis of ionized microbiological.
Time Trends of Surgical Outcome in Patients with Non-small Cell Lung Cancer  Takeshi Hanagiri, MD, PhD, Tetsuro Baba, MD, PhD, Tetsuya So, MD, PhD, Manabu.
Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence 
Presentation transcript:

Proteomic Strategies for the Characterization and the Early Detection of Lung Cancer  Pierre P. Massion, MD, Richard M. Caprioli, PhD  Journal of Thoracic Oncology  Volume 1, Issue 9, Pages 1027-1039 (November 2006) DOI: 10.1016/S1556-0864(15)31639-7 Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Schematic representation of identification of the components of a complex protein mixture through top-down and bottom-up proteomic approaches. 2D-Page, two-dimensional polyacrylamide gel electrophoresis; MS-MS, tandem mass spectrometry; MALDI TOF MS; matrix-assisted laser desorption time-of-flight mass spectrometry; LC MS-MS, liquid chromatography tandem mass spectrometry; Thermo LTQ, linear ion trap mass spectrometer. Journal of Thoracic Oncology 2006 1, 1027-1039DOI: (10.1016/S1556-0864(15)31639-7) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Schematic representation of matrix-assisted desorption ionization mass spectrometry. Fresh tissue is sectioned and mounted on a conductive metal plate. The sample is coated with matrix in a raster design, typically sinapinic acid, and directly analyzed in the mass spectrometer. The relative intensity of any of the signals in the spectrum is measured over the entire tissue at higher image resolution. If a small number of discrete areas are to be analyzed, then these are ablated individually in a profiling mode. If the relative intensity of any of the signals in the spectrum is to be measured over the entire tissue at higher image resolution, then a raster is performed to provide a matrix of pixels in an imaging mode. An image representing the intensity of a given peak in each pixel in the array is then generated. Journal of Thoracic Oncology 2006 1, 1027-1039DOI: (10.1016/S1556-0864(15)31639-7) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 (A), 2D-PAGE gel separation of proteins identified with silver staining from a stage I lung adenocarcinoma. The proteins are separated by isoelectric point (PI) in the first dimension and by molecular weight (MW) in the second dimension. (B–F), the outlined areas of (A) showing proteins significantly increased in lung adenocarcinoma (Chen G, Gharib TG, Huang CC, et al. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res 2002;8:2298–2305. Reprinted by permission. Journal of Thoracic Oncology 2006 1, 1027-1039DOI: (10.1016/S1556-0864(15)31639-7) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Tissue microarrays (TMAs) of lung cancer specimens. TMAs are comprised of core biopsies 0.6 mm in diameter of different tumors and of uninvolved lung from the same individuals. TMAs allow high-throughput analysis of molecular markers identified in lung cancer and control samples. Clinical annotation of these specimens allows rapid assessment of clinical outcomes (e.g., survival) as schematically represented by Kaplan-Meier survival curves. FISH, fluorescent in situ hybridization; IHC, immunohistochemistry. Journal of Thoracic Oncology 2006 1, 1027-1039DOI: (10.1016/S1556-0864(15)31639-7) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 Detection of the optimal discriminatory biomarker sets in lung tumors. (Top), Representative MALDI-TOF-MS spectra obtained from tumor and normal lung tissue samples with molecular weight calculation (m/z values). *Examples of the MS peaks identified by the statistical analyses as optimal discriminatory patterns between normal and tumor. (Bottom), Hierarchical cluster analysis of 42 lung tumors and eight normal lung tissues in the training cohort according to the protein expression patterns of 82 MS signals. Each row represents an individual proteomic signal, and each column represents an individual sample. The dendrogram at the top shows the similarity in protein expression profiles of the samples. Substantially raised (red) expression of the proteins is noted in individual tumor and normal lung tissue samples. AD, adenocarcinoma; SQ, squamous cell carcinoma; LA, large cell carcinoma; META, metastases to lung from other sites; REC, recurrent non-small cell lung cancer; CAR, pulmonary carcinoid; NL, normal lung. (Yanagisawa K, Shyr Y, Xu BJ, et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 2003; 362:433–439. Reprinted by permission.) Journal of Thoracic Oncology 2006 1, 1027-1039DOI: (10.1016/S1556-0864(15)31639-7) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions